Periprocedural Myocardial Infarction in Contemporary Practice

David W Lee; Matthew A Cavender

doi:10.1016/j.iccl.2018.12.001

Periprocedural Myocardial Infarction in Contemporary Practice

Interv Cardiol Clin. 2019 Apr;8(2):209-223. doi: 10.1016/j.iccl.2018.12.001. Epub 2019 Jan 28.

Authors

David W Lee¹, Matthew A Cavender²

Affiliations

¹ Division of Interventional Cardiology, University of North Carolina, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599, USA. Electronic address: David.Lee@unchealth.unc.edu.
² Division of Interventional Cardiology, University of North Carolina, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599, USA.

PMID: 30832943
DOI: 10.1016/j.iccl.2018.12.001

Abstract

"Periprocedural myocardial infarction (MI) occurs infrequently in the current era of percutaneous coronary interventions (PCI) and is associated with an increased risk of mortality and morbidity. Periprocedural MI can occur due to acute side branch occlusion, distal embolization, slow flow or no reflow phenomenon, abrupt vessel closure, and nonidentifiable mechanical processes. Therapeutic strategies to reduce the risk of periprocedural MI include dual antiplatelet therapy, intravenous cangrelor in the periprocedural setting, intravenous glycoprotein IIb/IIIa inhibitor in high-risk patients, anticoagulation with unfractionated heparin, low-molecular-weight heparin or bivalirudin, and embolic protection devices during saphenous vein graft interventions."

Keywords: Myocardial infarction; Percutaneous coronary intervention; Periprocedural myocardial infarction.

Publication types

Review

MeSH terms

Coronary Occlusion / complications*
Embolic Protection Devices*
Humans
Myocardial Infarction / etiology
Myocardial Infarction / therapy*
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use*
Preoperative Care / methods*
Treatment Outcome

Substances

Platelet Aggregation Inhibitors